Clinical Trials Logo

Influenza, Human clinical trials

View clinical trials related to Influenza, Human.

Filter by:

NCT ID: NCT05312294 Completed - Influenza Clinical Trials

Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years

Start date: December 7, 2020
Phase: Phase 3
Study type: Interventional

Comparative assessment of the tolerability, safety, and immunogenicity of the Flu-M® Inactivated Split Influenza Vaccine (without preservative) and the Flu-M® vaccine (with preservative) in volunteers aged between 18 and 60

NCT ID: NCT05308212 Completed - Influenza Clinical Trials

Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra

Start date: March 4, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Comparative assessment of the tolerability, safety, and immunogenicity of the FLU-M® Tetra quadrivalent inactivated split influenza vaccine and the Ultrix® vaccine in volunteers aged 60 years and above.

NCT ID: NCT05297994 Completed - Influenza Clinical Trials

Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA

Start date: October 24, 2016
Phase: Phase 2
Study type: Interventional

To trial the reactogenicity, safety and immunogenicity of the Flu-M inactivated split influenza vaccine in volunteers aged 18-60 years

NCT ID: NCT05284799 Completed - Influenza Clinical Trials

Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.

Start date: May 9, 2022
Phase: Phase 2
Study type: Interventional

The present study will evaluate the concomitant administration of a Quadrivalent Inactivated Influenza Vaccine with the highest dose level of OVX836 (480µg) tested in the clinic to date, for which the likelihood for interference with Quadrivalent Inactivated Influenza Vaccine is considered the highest.

NCT ID: NCT05273619 Completed - Influenza, Human Clinical Trials

Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

Start date: May 23, 2022
Phase: Phase 3
Study type: Interventional

Study to assess the efficacy and safety of XC8, film-coated tablets, 10 mg in comparison with placebo in patients with dry non-productive cough against acute respiratory infection.

NCT ID: NCT05269329 Completed - Influenza, Human Clinical Trials

Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

Start date: April 26, 2021
Phase: Phase 2
Study type: Interventional

Study to assess the efficacy and safety of XC8, film-coated tablets, 10 mg in comparison with placebo in patients with dry non-productive cough against acute respiratory infections, and to determine the dosing regimen of XC8, film-coated tablets, 10 mg for treatment of dry non-productive cough against acute respiratory infections.

NCT ID: NCT05269290 Completed - Influenza, Human Clinical Trials

Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections

Start date: September 23, 2021
Phase: Phase 3
Study type: Interventional

The study is planned to evaluate the therapeutic efficacy and safety of Ingavirin®, syrup, 30 mg/5 ml, in the treatment of influenza or other acute respiratory infections in children from 6 months to 2 years compared with placebo.

NCT ID: NCT05268939 Completed - COVID-19 Clinical Trials

Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19

INSPIRE-2
Start date: January 4, 2022
Phase: N/A
Study type: Interventional

A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 & FLU A/B Test, and LumiraDx SARS-CoV-2 & RSV Test at Point of Care Testing Sites. Subjects presenting with symptoms suggestive of COVID-19 and/or Influenza and/or RSV will be consented and asked to donate swab sample(s) for testing in the device(s) under evaluation.

NCT ID: NCT05255822 Completed - Clinical trials for Influenza Prophylaxis

INNA-051 Influenza Challenge Study

Start date: February 28, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in healthy adults, administered prior to administration of an influenza challenge virus. This study will evaluate 2 active dose levels of INNA-051 and placebo.

NCT ID: NCT05252338 Completed - Influenza Clinical Trials

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults

Start date: February 7, 2022
Phase: Phase 1
Study type: Interventional

This study aims to evaluate the safety and reactogenicity profile of CVSQIV at different dose levels.